Project description:Whether severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection can be asymptomatic is unclear. We examined the seroprevalence of SARS-CoV among 674 healthcare workers from a hospital in which a SARS outbreak had occurred. A total of 353 (52%) experienced mild self-limiting illnesses, and 321 (48%) were asymptomatic throughout the course of these observations. None of these healthcare workers had antibody to SARS CoV, indicating that subclinical or mild infection attributable to SARS-CoV in adults is rare.

| S-EPMC3035556 | biostudies-literature

Severe acute respiratory syndrome coronavirus 2

Project description:Clinical Experience of Treatment of Immunocompromised Individuals with Persistent SARS-CoV-2 Infection Based on Drug Resistance Mutations Determined by Genomic Analysis: A Descriptive Study

| PRJDB16147 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:NYC SARS-CoV-2 Genome sequencing and assembly

| PRJNA704697 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Severe acute respiratory syndrome coronavirus 2 Raw sequence reads

| PRJNA722947 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Severe acute respiratory syndrome coronavirus 2 Genome sequencing and assembly

| PRJNA973015 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Raw sequence reads of SARS-CoV-2 from a case of donor derived infection by lung transplantation

| PRJNA679980 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:SARS-CoV-2 genomic data and descriptive metadata from primary specimens collected in Manitoba, Canada during the COVID-19 outbreak

| PRJNA669043 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Genomic Epidemiology of COVID in the Philippines (MR/V035444/1)

| PRJNA951874 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications

| PRJNA1002985 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data